April 1, 2022
- Integrated portfolio for atrial fibrillation offers solutions
across electrophysiology, cardiac implantable electronic device
(CIED) lead extraction and ECG monitoring
- New release of KODEX-EPD cardiac imaging and mapping
system from Philips incorporates new innovations for RF and
cryoballoon therapy for cardiac arrhythmias
- Philips reinforces its commitment to facilitating adherence to
international best-practice guidelines for lead management and lead
extraction
- Wearable ePatch Holter monitor aids diagnosis and follow-up of
atrial fibrillation patients to reduce stroke risk
Amsterdam, the Netherlands – Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology, is
showcasing its integrated portfolio of diagnosis, guidance, and
treatment solutions for atrial fibrillation at the 2022 European
Heart Rhythm Association Annual Meeting (EHRA 2022, April 3-5,
Copenhagen, Denmark). A key highlight in the company’s booth that
will support the treatment of the growing number of patients with
atrial fibrillation will be the launch of the latest release of the
KODEX-EPD system from Philips. It offers enhanced imaging and
mapping capabilities for RF ablation, including the new Tissue
Engagement Viewer and support for the Medtronic DiamondTempTM
ablation system. For cryoballoon ablation, KODEX-EPD supports a new
saline-based occlusion assessment workflow [1].
Other highlights include enhancements to the company’s
Electrophysiology Suite; the company’s newest lead management tools
for the safe removal of infected cardiac implantable electronic
device (CIED) leads; and Philips’ unobtrusive wearable ePatch
extended wear Holter monitoring service, which is part of the
Philips Ambulatory Monitoring and Diagnostics portfolio. Providing
support for confident diagnosis, enhanced electrophysiology (EP)
procedure efficacy and efficiency, reduced X-ray exposure, and
post-procedure therapy monitoring, these new innovations
significantly elevate the physician’s experience towards optimal
treatment of atrial fibrillation (AF) patients.
Atrial fibrillation is the world’s most common cardiac
arrhythmia, with a particularly high prevalence in developed
countries, partly due to lifestyle and an aging population. The
condition, which also significantly increases the risk of stroke,
dementia, and heart failure, already affects around 37 million
people worldwide (approximately 0.5% of the world’s population)[2]
- a number that is predicted to double in the next 40 years.
Philips’ electrophysiology and cardiac lead extraction solutions
uniquely leverage imaging systems and software with specialized
diagnostic and therapeutic devices designed to support the
treatment of the growing number of patients with heart rhythm
disorders. Running on the company’s Azurion platform, Philips
Electrophysiology Suite seamlessly integrates imaging, devices,
software, informatics, and services. It assists at every stage of
an atrial fibrillation patient’s journey, providing cardiologists
with greater insight and confidence in electrophysiology procedures
while allowing them to meet increasing clinical demand at
affordable cost.
New KODEX-EPD release with expanded
compatibilityThe latest release of KODEX-EPD, launched at
EHRA, features a range of innovations for both RF and cryoballoon
ablation therapy. Enhanced imaging and mapping capabilities support
physicians with precise RF ablation procedures, including the new
Tissue Engagement Viewer that provides information about
catheter-tissue contact without the need for special catheters.
Philips has expanded the compatibility of the KODEX-EPD system
to support the Medtronic DiamondTempTM ablation system for
real-time, temperature-controlled ablation. For cryoballoon
ablation, the KODEX-EPD system features a new saline-based
occlusion assessment workflow [1], which further reduces the need
for X-ray imaging with iodinated contrast media, which is
particularly valuable for patients with allergies to iodine or
chronic kidney disease.
Philips continues to engage with Medtronic to support physicians
in ablation procedures to optimize patient outcomes and minimize
exposure to X-ray and iodinated contrast media. The results of
these activities will be presented during the EHRA congress at
various scientific sessions and a Philips-sponsored symposium.
CIED lead extraction and lead managementCardiac
implantable electronic devices (CIEDs) such as pacemakers,
implantable cardioverter defibrillators (ICDs), and cardiac
resynchronization therapy (CRT) devices are life-saving devices
that improve quality of life for many patients. However, 1 in 20 of
these patients develop a CIED infection [3] within three years.
Patients diagnosed with CIED infections are often treated with
antibiotics, which is not an effective treatment option on its own.
50%-100% of patients treated solely with antibiotics will
experience an infection relapse [4,5].A large EHRA survey conducted
in 2020 demonstrated that medical professionals lack awareness and
experience in CIED infection management [6]. According to the
latest European Heart Rhythm Association (EHRA) International
Consensus Document [7], definite CIED infections are a Class I
indication for full device extraction. Nevertheless, it is
estimated that more than 75% of indicated patients do not receive
Class I guideline care, which is a full system extraction, leading
to negative health outcomes and higher costs. Philips is committed
to supporting evidence-based medical approaches and innovating
solutions to help physicians improve outcomes and decrease
mortality for CIED infection.Although adverse events during a
procedure can potentially be life threatening, lead extraction is a
highly successful, potentially life-saving procedure with a
clinical success rate of 97.7% and a procedural safety rate of
99.72% [8]. Philips supports physicians with Lead Management
solutions through a broad portfolio of tools designed for safety
and predictability, including both laser and mechanical lead
extraction devices.Philips ePatch When diagnosing
AF - a heart irregularity that can lead to blood clots and increase
the risk of stroke - it is important to record its frequency,
duration, and severity. It is equally important to check that
irregularities do not recur in the days and weeks after therapy.
While conventional Holter monitors that perform these evaluations
have been around for a long time, they typically involve the
attachment of up to seven ECG electrodes to the patient’s chest,
linked to a belt-worn control unit. These can be cumbersome for
patients to wear - which can impact the diagnostic yield - while
the application process, data analysis and reporting can be
labour-intensive and inefficient for clinical staff. Philips ePatch
replaces this cumbersome set-up with a small unobtrusive sensor and
patch(es) adhered to the patient’s sternum for up to 14 days of
continuous, high-quality ECG recording for reliable diagnosis.
Philips ePatch is splash proof, it can be worn in the shower and
enables the patient to keep an active lifestyle. Philips also
provides an end-to-end service for ePatch deployment, supporting
efficient workflows, enhancing the patient experience and enabling
robust data analysis using our cloud-based AI-enabled Cardiologs
software. For more information and to register for the Philips Lead
Management scientific session with an expert infectiologist and
cardiologist or our session on the evolution of dielectric imaging
and next-generation ECG monitoring, please visit Philips’ EHRA 2022
webpages.
[1] For use exclusively with Medtronic Arctic Front Advance™
cryoablation catheters.[2] GBD 2017 Disease and Injury Incidence
and Prevalence Collaborators, Global, regional, and national
incidence, prevalence, and years lived with disability for 354
diseases and injuries for 195 countries and territories, 1990-2017:
a systematic analysis for the Global Burden of Disease Study 2017.
Lancet. 2018; 392: 1789-1858.[3] Cantillon D, et al. Complications
and Health Care Costs Associated With Transvenous Cardiac
Pacemakers in a Nationwide Assessment. J Am Coll Cardiol EP. 2017
Nov, 3 (11) 1296–1305.[4] del Rio A, Anguera I, Miro JM, et al.
Surgical treatment of pacemaker and defibrillator lead
endocarditis: the impact of electrode lead extraction on outcome.
Chest 2003;124:1451–9.[5] Chua, J.D., et al. (2000). Diagnosis and
management of infections involving implantable
electrophysiologic.[6] Archana Rao et al 2020 Knowledge gaps, lack
of confidence, and system barriers to guideline implementation
among European physicians managing patients with CIED lead or
infection complications: a European Heart Rhythm
Association/European Society of Cardiology educational needs
assessment survey. Europace (2020) 0, 1.[7] Blomström-Lundqvist C,
Traykov V, Erba PA, et al. EP Europace, Volume 22, Issue 4, April
2020, Pages 515–549, https://doi.org/10.1093/europace/euz246.[8]
Wazni, O. et. al. Lead Extraction in the Contemporary Setting: The
LExICon Study: A Multicenter Observational RetrospectiveStudy of
Consecutive Laser Lead Extractions, J Am Coll Cardiol,
55:579-586.
DiamondTemp and Arctic Front Advance are trademarks of Medtronic
companies.
For further information, please contact:
Joost Maltha Philips Global Press Office Tel:
+31 6 10 55
8116 E-mail: joost.maltha@philips.com
Fabienne van der FeerPhilips Image Guided TherapyTel: + 31 622
698 001E-mail: fabienne.van.der.feer@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
well-being, and enabling better outcomes across the health
continuum – from healthy living and prevention, to diagnosis,
treatment and home care. Philips leverages advanced technology and
deep clinical and consumer insights to deliver integrated
solutions. Headquartered in the Netherlands, the company is a
leader in diagnostic imaging, image-guided therapy, patient
monitoring and health informatics, as well as in consumer health
and home care. Philips generated 2021 sales of EUR 17.2 billion and
employs approximately 78,000 employees with sales and services in
more than 100 countries. News about Philips can be found at
www.philips.com/newscenter.
- KODEX-EPD cardiac imaging and mapping system from Philips
- Philips KODEX-EPD cryoballoon procedure
- Philips GlideLight Laser Sheath for lead management
- Philips ePatch high-quality ECG recording
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Sep 2023 to Sep 2024